Preclinical Evaluation of Long-Acting Emtricitabine Semi-Solid Prodrug Nanoparticle Formulations.
HIV
emtricitabine
long-acting
nano
pre-exposure prophylaxis
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
27 Jun 2023
27 Jun 2023
Historique:
received:
22
05
2023
revised:
14
06
2023
accepted:
20
06
2023
medline:
29
7
2023
pubmed:
29
7
2023
entrez:
29
7
2023
Statut:
epublish
Résumé
Long-acting injectable (LAI) formulations promise to deliver patient benefits by overcoming issues associated with non-adherence. A preclinical assessment of semi-solid prodrug nanoparticle (SSPN) LAI formulations of emtricitabine (FTC) is reported here. Pharmacokinetics over 28 days were assessed in Wistar rats, New Zealand white rabbits, and Balb/C mice following intramuscular injection. Two lead formulations were assessed for the prevention of an HIV infection in NSG-cmah
Identifiants
pubmed: 37514020
pii: pharmaceutics15071835
doi: 10.3390/pharmaceutics15071835
pmc: PMC10383755
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NIH HHS
ID : R01AI114405-01
Pays : United States
Références
Ther Deliv. 2011 May;2(5):643-72
pubmed: 21837267
J Int Assoc Provid AIDS Care. 2021 Jan-Dec;20:23259582211009011
pubmed: 33902356
HIV Med. 2004 Mar;5(2):99-104
pubmed: 15012649
J Infect Dis. 2016 May 15;213(10):1519-20
pubmed: 26681779
Curr Opin HIV AIDS. 2013 Nov;8(6):565-71
pubmed: 24100877
Ment Health Clin. 2018 Mar 26;8(2):56-62
pubmed: 29955546
Expert Opin Investig Drugs. 2015;24(9):1219-28
pubmed: 26088266
BMC Immunol. 2019 Jan 7;20(1):2
pubmed: 30616506
AIDS. 2017 Mar 27;31(6):765-770
pubmed: 28099191
Ther Adv Psychopharmacol. 2014 Oct;4(5):198-219
pubmed: 25360245
Clin Pharmacokinet. 2015 Jun;54(6):639-50
pubmed: 25523214
J Appl Toxicol. 2001 Jan-Feb;21(1):15-23
pubmed: 11180276
HIV Med. 2023 Feb;24(2):202-211
pubmed: 35945163
J Virol. 2014 Jul;88(13):7589-601
pubmed: 24760888
J Acquir Immune Defic Syndr. 2013 Mar 1;62(3):275-81
pubmed: 23274933
Cureus. 2016 Mar 01;8(3):e515
pubmed: 27054050
J Control Release. 2016 May 28;230:95-108
pubmed: 27067365
J Antimicrob Chemother. 2022 Mar 31;77(4):1094-1101
pubmed: 35022753
Nat Med. 2012 Sep;18(9):1378-85
pubmed: 22941277
J Int AIDS Soc. 2005 Jul 07;7(3):69
pubmed: 19825134
Biopharm Drug Dispos. 2012 Jul;33(5):265-77
pubmed: 22610784
Clin Infect Dis. 2006 Jan 1;42(1):126-31
pubmed: 16323102
CNS Drugs. 2017 Jul;31(7):617-624
pubmed: 28597226
AIDS Rev. 2015 Jan-Mar;17(1):3-20
pubmed: 25427100
J Pharm Pharm Sci. 2010;13(3):428-42
pubmed: 21092714
J Acquir Immune Defic Syndr. 2016 Aug 1;72(4):444-51
pubmed: 26990823
Curr Rev Clin Exp Pharmacol. 2021;16(1):109-116
pubmed: 32148198
AIDS. 2012 Nov 13;26(17):2135-44
pubmed: 22824628
Future Sci OA. 2017 Sep 06;4(1):FSO230
pubmed: 29255619
Front Cell Infect Microbiol. 2020 Feb 11;10:38
pubmed: 32117811
Nat Commun. 2019 Mar 29;10(1):1413
pubmed: 30926773
Nat Commun. 2018 Feb 6;9(1):443
pubmed: 29402886
Nanomedicine (Lond). 2013 Nov;8(11):1807-13
pubmed: 23611617
Glob Health Sci Pract. 2014 Mar 26;2(2):182-94
pubmed: 25276576
Eur J Pharm Biopharm. 2019 May;138:92-98
pubmed: 29684534